Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical

Tumor mutational burden as a prognostic biomarker for survival and quality of life in metastatic colorectal cancer patients receiving anti-PD-1/PD-L1 immunotherapy: A retrospective cohort study

Summary

This retrospective study assessed the prognostic value of tumor mutational burden (TMB) in 221 patients with metastatic colorectal cancer (mCRC) receiving anti-PD-1/PD-L1 immunotherapy combined with standard chemotherapy. Patients with high TMB (TMB-H) demonstrated significantly improved progression-free survival and overall survival compared to those with low TMB (TMB-L). Furthermore, the TMB-H group reported a better post-treatment quality of life, with no increase in adverse events. These findings suggest that TMB-H is a positive prognostic biomarker in this patient population and warrant prospective validation.

Critical appraisal

This retrospective cohort study (n=221) identifies high tumor mutational burden (TMB-H) as a significant prognostic biomarker for metastatic colorectal cancer patients treated with anti-PD-1/PD-L1 immunotherapy. TMB-H patients demonstrated significantly improved progression-free survival (PFS) and overall survival (OS) (P < .001), along with a better quality of life, without an increase in adverse events. These findings, while from a retrospective study, are important as they suggest TMB could help stratify patients and guide therapeutic decisions. Prospective validation is warranted, but these data could, in the long term (3-5 years), influence clinical guidelines for selecting patients eligible for immunotherapy beyond MSI-H/dMMR indications.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology